AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17367658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 672
Study 17367658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 672
Study 17367658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 672
Study 17367658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 17367658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (all doses)
Number of subjects: 672
Study 15253102 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate (14 patients)
Number of subjects: 28
Study 15253102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (14 patients)
Number of subjects: 28
Study 11454260 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fresh platelet concentrate (PC); n = 24
Number of subjects: 48
Study 11454260 — intervention group
Group type: COMPARATOR
Intervention: Autologous fresh whole blood (WB); n = 24
Number of subjects: 48
Study 9789646 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of antibiotics
Number of subjects: 0
Study 9789646 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7811656 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intranasal midazolam
Number of subjects: 43
Study 7811656 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intranasal midazolam
Number of subjects: 43
Study 3379200 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency analysis with fast Fourier transform and time domain analysis after signal averaging and high gain, low noise amplification (0 to 300 Hz) in patients with ventricular tachycardia.
Number of subjects: 60
Study 3379200 — intervention group
Group type: COMPARATOR
Intervention: Patients without ventricular tachycardia after infarction.
Number of subjects: 60
Study 3379200 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects.
Number of subjects: 60
Study 31980145 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 716
Study 31980145 — intervention group
Group type: COMPARATOR
Intervention: ECF/ECX regimen (epirubicin, cisplatin, and 5-fluorouracil or capecitabine)
Number of subjects: 716
Study 30803175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium sulfate solution in split doses (group A, n=178)
Number of subjects: 368
Study 30803175 — intervention group
Group type: COMPARATOR
Intervention: Single dose group (group B, n=190)
Number of subjects: 368
Study 29327733 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliance (Modify Monobloc, MM)
Number of subjects: 51
Study 29327733 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional therapy of mandibular advancement
Number of subjects: 51
Study 29327733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance
Number of subjects: 51
Study 29327733 — intervention group
Group type: COMPARATOR
Intervention: Untreated Class II malocclusion
Number of subjects: 51
Study 25400085 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 25
Study 25400085 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily regimen of oral hydrocortisone (OHC)
Number of subjects: 25
Study 23702187 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Eating Restriction (NER) for 2 weeks (elimination of energy intake from 19.00 to 06.00 hours)
Number of subjects: 29
Study 23702187 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Eating Restriction (NER)
Number of subjects: 29
Study 23702187 — intervention group
Group type: COMPARATOR
Intervention: Control condition for 2 weeks
Number of subjects: 29
Study 23702187 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 29
Study 21534679 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message with fear induction
Number of subjects: 133
Study 21534679 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message with anger induction
Number of subjects: 133
Study 21534679 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched message frame to emotional state
Number of subjects: 133
Study 18465720 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM hydrophilic acrylic IOL (BioVue3)
Number of subjects: 100
Study 18465720 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (Sensar)
Number of subjects: 100
Study 16856905 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 MU s.c. three times a week for 6 months)
Number of subjects: 167
Study 16856905 — intervention group
Group type: COMPARATOR
Intervention: No IFN-alpha (control group)
Number of subjects: 167
Study 16856905 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 167
Study 16856905 — intervention group
Group type: COMPARATOR
Intervention: No IFN-alpha
Number of subjects: 167
Study 12558913 — intervention group
Group type: COMPARATOR
Intervention: CIFN 9 microg daily
Number of subjects: 40
Study 12558913 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 9 microg daily plus ribavirin 1000 or 1200 mg daily
Number of subjects: 40
Study 10736983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/die)
Number of subjects: 53
Study 10736983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/die)
Number of subjects: 53
Study 8757573 — intervention group
Group type: EXPERIMENTAL
Intervention: Study subjects (intervention group)
Number of subjects: 209
Study 8757573 — intervention group
Group type: EXPERIMENTAL
Intervention: Study women (intervention group)
Number of subjects: 209
Study 8757573 — intervention group
Group type: EXPERIMENTAL
Intervention: Study men (intervention group)
Number of subjects: 209
Study 8757573 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 209
Study 1601147 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) - leuprolide acetate (500 micrograms)
Number of subjects: 179
Study 1601147 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotropin (hCG) - 5,000 IU
Number of subjects: 179
Study 6397871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral anticoagulation with shorter heparin treatment
Number of subjects: 169
Study 6397871 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral anticoagulation with conventional heparin treatment
Number of subjects: 169
Study 6397871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral anticoagulation with shorter heparin treatment (second part of the study)
Number of subjects: 169
Study 6397871 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral anticoagulation with conventional heparin treatment (second part of the study)
Number of subjects: 169
Study 31144435 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP1RA plus basal insulin
Number of subjects: 120
Study 31144435 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin
Number of subjects: 120
Study 29720084 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART MOVE intervention
Number of subjects: 18
Study 29720084 — intervention group
Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 18
Study 26990766 — intervention group
Group type: EXPERIMENTAL
Intervention: AQW051 10 mg
Number of subjects: 67
Study 26990766 — intervention group
Group type: EXPERIMENTAL
Intervention: AQW051 50 mg
Number of subjects: 67
Study 26990766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 24576194 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16
Study 24576194 — intervention group
Group type: COMPARATOR
Intervention: SHAM (no WBV)
Number of subjects: 16
Study 23537728 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat Githeri
Number of subjects: 902
Study 23537728 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Githeri (githeri+oil)
Number of subjects: 902
Study 23537728 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk Githeri
Number of subjects: 902
Study 23537728 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 902
Study 21253451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI)
Number of subjects: 247
Study 21253451 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS)
Number of subjects: 247
Study 17689205 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation treatment during alcohol treatment
Number of subjects: 499
Study 17689205 — intervention group
Group type: COMPARATOR
Intervention: Delayed smoking cessation treatment (6 months later)
Number of subjects: 499
Study 15897722 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of d-amphetamine
Number of subjects: 72
Study 15897722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12917721 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (intensive treatment)
Number of subjects: 43
Study 12917721 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (less intensive treatment)
Number of subjects: 43
Study 10622016 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by general practitioners (GPs)
Number of subjects: 1878
Study 10622016 — intervention group
Group type: COMPARATOR
Intervention: Usual A&E staff
Number of subjects: 1878
Study 10150320 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5-mg dose of ramipril
Number of subjects: 20
Study 10150320 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration of 5 mg of ramipril daily for 6 months
Number of subjects: 20
Study 10150320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2201190 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg per day for 2 days)
Number of subjects: 94
Study 2201190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 7003434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Shunt removal with systemic antibiotics, external ventricular drainage or intermittent ventricular taps for decompression and antibiotic administration; intravenous and intraventricular antibiotics for a minimum of 7 days.
Number of subjects: 30
Study 7003434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Removal and immediate replacement of the shunt with intrashunt antibiotic therapy; intravenous antibiotics for a minimum of 3 weeks and twice daily intraventricular antibiotics for a minimum of 2 weeks.
Number of subjects: 30
Study 7003434 — intervention group
Group type: COMPARATOR
Intervention: Group C: Antibiotics without removal or replacement of the shunt; intravenous antibiotics for a minimum of 3 weeks and twice daily intraventricular antibiotics for a minimum of 2 weeks.
Number of subjects: 30
Study 30975954 — intervention group
Group type: EXPERIMENTAL
Intervention: 150‐mg oral pregabalin and 400 mg IV ibuprofen
Number of subjects: 90
Study 30975954 — intervention group
Group type: EXPERIMENTAL
Intervention: 75‐mg oral pregabalin and 400‐mg IV ibuprofen
Number of subjects: 90
Study 30975954 — intervention group
Group type: COMPARATOR
Intervention: 400‐mg IV ibuprofen
Number of subjects: 90
Study 30975954 — intervention group
Group type: COMPARATOR
Intervention: oral placebo and IV placebo
Number of subjects: 90
Study 30975954 — intervention group
Group type: COMPARATOR
Intervention: oral placebo and 400‐mg IV ibuprofen
Number of subjects: 90
Study 28231660 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment during second and third trimesters of pregnancy
Number of subjects: 321
Study 28231660 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 321
Study 28231660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telbivudine treatment)
Number of subjects: 321
Study 26297142 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² followed by cisplatin 75 mg/m² (Arm A)
Number of subjects: 94
Study 26297142 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + cisplatin with esomeprazole (ESOM) 80 mg p.o. bid for 3 days (Arm B)
Number of subjects: 94
Study 26297142 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + cisplatin with esomeprazole (ESOM) 100 mg p.o. bid for 3 days (Arm C)
Number of subjects: 94
Study 26297142 — intervention group
Group type: COMPARATOR
Intervention: PPI (Proton Pump Inhibitors) vs no PPI
Number of subjects: 94
Study 26297142 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI combination in triple negative breast cancer (TNBC)
Number of subjects: 94
Study 26297142 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI combination effect on overall survival (OS)
Number of subjects: 94
Study 23273588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mL/d fluid restriction
Number of subjects: 46
Study 23273588 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 22040597 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual chiropractic care
Number of subjects: 180
Study 22040597 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (de-tuned ultrasound and de-tuned activator treatment)
Number of subjects: 180
Study 22040597 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 180
Study 19148431 — intervention group
Group type: COMPARATOR
Intervention: 2 g of IV cephazolin in the anesthetic induction (Group C)
Number of subjects: 0
Study 19148431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of tinidazole orally, 12 hours before the surgery (Group T)
Number of subjects: 0
Study 19148431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of tinidazole orally 12 hours before the surgery and 2g of IV cephazolin in the anesthetic induction (Group C+T)
Number of subjects: 0
Study 16572441 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with etanercept (25 mg subcutaneously twice weekly) and oral MTX (up to 20 mg weekly)
Number of subjects: 503
Study 16572441 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly)
Number of subjects: 503
Study 16572441 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (up to 20 mg weekly)
Number of subjects: 503
Study 14599040 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Kcal/dL formula (group A)
Number of subjects: 0
Study 14599040 — intervention group
Group type: COMPARATOR
Intervention: 70 Kcal/dL formula (group B)
Number of subjects: 0
Study 11138459 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (70 mg/m2) days 1 and 8 every 4 weeks
Number of subjects: 155
Study 11138459 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (60 mg/m2) days 1 and 8 plus cisplatin (100 mg/m2) day 1 every 4 weeks
Number of subjects: 155
Study 1567032 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 micrograms/10 mL
Number of subjects: 60
Study 1567032 — intervention group
Group type: COMPARATOR
Intervention: Normal saline-control 10 mL
Number of subjects: 60
Study 3926067 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream, applied topically five times a day for five days
Number of subjects: 45
Study 3926067 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 45
Study 3926067 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study 30057223 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental radial nerve release
Number of subjects: 54
Study 30057223 — intervention group
Group type: COMPARATOR
Intervention: No radial nerve release
Number of subjects: 54
Study 30509268 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct inhalation technique
Number of subjects: 165
Study 30509268 — intervention group
Group type: COMPARATOR
Intervention: Incorrect inhalation technique
Number of subjects: 165
Study 26252976 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually modified contours (MOD)
Number of subjects: 64
Study 26252976 — intervention group
Group type: COMPARATOR
Intervention: Automated method (AUTO)
Number of subjects: 64
Study 24802657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 2 mg
Number of subjects: 22
Study 24802657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 4 mg
Number of subjects: 22
Study 24802657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23158229 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal worm infections (Mansonella perstans)
Number of subjects: 983
Study 23158229 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal worm infections (Strongyloides stercoralis)
Number of subjects: 983
Study 23158229 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anthelminthic treatment during pregnancy
Number of subjects: 983
Study 20926997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of corticosteroid
Number of subjects: 0
Study 20926997 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 18514620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amino acid supplements alongside ACE inhibitor therapy
Number of subjects: 0
Study 18514620 — intervention group
Group type: COMPARATOR
Intervention: Placebo alongside ACE inhibitor therapy
Number of subjects: 0
Study 15928545 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment and group exercise
Number of subjects: 0
Study 15928545 — intervention group
Group type: COMPARATOR
Intervention: Back advice booklet and one session of advice
Number of subjects: 0
Study 12074417 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile inhalation induction and maintenance (Group 1)
Number of subjects: 30
Study 12074417 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia with propofol and a minimal dose sufentanil (Group 2)
Number of subjects: 30
Study 12074417 — intervention group
Group type: COMPARATOR
Intervention: Moderate dose midazolam-sufentanil (Group 3)
Number of subjects: 30
Study 12074417 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 10385780 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 10
Study 10385780 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg/day)
Number of subjects: 10
Study 8671815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium withdrawal
Number of subjects: 13
Study 8671815 — intervention group
Group type: COMPARATOR
Intervention: Non-lithium control
Number of subjects: 13
Study 1501360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysate-containing product
Number of subjects: 20
Study 1501360 — intervention group
Group type: COMPARATOR
Intervention: Intact milk protein product
Number of subjects: 20
Study 1501360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hydrolysate and Intact milk protein)
Number of subjects: 20
Study 6849733 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pindolol eye drops
Number of subjects: 12
Study 6849733 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% pindolol eye drops
Number of subjects: 12
Study 30762274 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar infliximab) in the maintenance group
Number of subjects: 380
Study 30762274 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 (biosimilar infliximab) in the switch group
Number of subjects: 380
Study 30762274 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar infliximab)
Number of subjects: 380
Study 28298024 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-1 receptor antagonist (IL-1Ra) 100 mg administered twice daily for up to 21 days postictus.
Number of subjects: 100
Study 26671909 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based psychological intervention (values affirmations)
Number of subjects: 0
Study 24517632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C group (<40 mg/dL)
Number of subjects: 120
Study 24517632 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized HDL-C levels
Number of subjects: 120
Study 24517632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 120
Study 22809906 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Number of subjects: 509
Study 22809906 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 509
Study 20170522 — intervention group
Group type: EXPERIMENTAL
Intervention: LeptiCore formula A (low dose)
Number of subjects: 92
Study 20170522 — intervention group
Group type: EXPERIMENTAL
Intervention: LeptiCore formula B (high dose)
Number of subjects: 92
Study 20170522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 17567340 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI propofol driven by the Schnider model in effect site control
Number of subjects: 40
Study 17567340 — intervention group
Group type: COMPARATOR
Intervention: TCI propofol driven by the Marsh model in plasma control
Number of subjects: 40
Study 15606439 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine (10 mg for 14 kg to <24 kg; 20 mg for ≥24 kg)
Number of subjects: 124
Study 15606439 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine (20 mg)
Number of subjects: 124
Study 11911720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) for 1 year during PEPI-RCT
Number of subjects: 495
Study 11911720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) for 3 years during PEPI-RCT
Number of subjects: 495
Study 11911720 — intervention group
Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 495
Study 11911720 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued Hormone Replacement Therapy (HRT) after PEPI-RCT
Number of subjects: 495
Study 10102410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (0.51 mg as a single daily dose 2 hours before bedtime)
Number of subjects: 30
Study 10102410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8751230 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment I (B 5 ml, OT 500 mg, M 200 mg, q.i.d. for 14 days)
Number of subjects: 306